Therapeutic management of adrenal insufficiency

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 23, Issue 2, 2009, Pages 167-179

  Hahner, Stefanie ^a   Allolio, Bruno ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Addison's disease; adrenal crisis; adrenal insufficiency; DHEA; mineralocorticoid glucocorticoid replacement

Indexed keywords

ALDOSTERONE; CORTISONE ACETATE; FLUDROCORTISONE; GLUCOCORTICOID; HYDROCORTISONE; MINERALOCORTICOID; PRASTERONE; PRASTERONE SULFATE; PREDNISOLONE; PREDNISONE;

ACNE; ADDISON DISEASE; ADRENAL CORTEX INSUFFICIENCY; ADRENAL INSUFFICIENCY; ADRENAL SUPPRESSION; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; DOSE RESPONSE; DRUG MECHANISM; DRUG METABOLISM; DRUG RELEASE; EMERGENCY CARE; HORMONE SUBSTITUTION; HUMAN; HYDROCORTISONE BLOOD LEVEL; LIFE EXPECTANCY; MORNING DOSAGE; PATIENT EDUCATION; PREGNANCY; REVIEW; RISK FACTOR; SEBUM SECRETION; SEPTIC SHOCK; SEXUAL FUNCTION; SIDE EFFECT; SINGLE DRUG DOSE; WELLBEING;

ADRENAL INSUFFICIENCY; DEHYDROEPIANDROSTERONE; FEMALE; GLUCOCORTICOIDS; HORMONE REPLACEMENT THERAPY; HUMANS; INTENSIVE CARE; MINERALOCORTICOIDS; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 66149171505     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2008.09.009     Document Type: Review

References (64)

1. Arlt W., and Allolio B. Adrenal insufficiency. Lancet 361 (2003) 1881-1893
2. Lovas K., Loge J.H., and Husebye E.S. Subjective health status in Norwegian patients with Addison's disease. Clinical Endocrinology 56 (2002) 581-588
3. Hahner S., Loeffler M., Fassnacht M., et al. Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. The Journal of Clinical Endocrinology and Metabolism 92 (2007) 3912-3922
4. Thomsen A.F., Kvist T.K., Andersen P.K., et al. The risk of affective disorders in patients with adrenocortical insufficiency. Psychoneuroendocrinology 31 (2006) 614-622
5. Bergthorsdottir R., Leonsson-Zachrisson M., Oden A., et al. Premature mortality in patients with Addison's disease: a population-based study. The Journal of Clinical Endocrinology and Metabolism 91 (2006) 4849-4853
6. Tomlinson J.W., Holden N., Hills R.K., et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 357 (2001) 425-431
7. Esteban N.V., and Yergey A.L. Cortisol production rates measured by liquid chromatography/mass spectrometry. Steroids 55 (1990) 152-158
8. Kerrigan J.R., Veldhuis J.D., Leyo S.A., et al. Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis. The Journal of Clinical Endocrinology and Metabolism 76 (1993) 1505-1510
9. Kraan G.P., Dullaart R.P., Pratt J.J., et al. The daily cortisol production reinvestigated in healthy men. The serum and urinary cortisol production rates are not significantly different. The Journal of Clinical Endocrinology and Metabolism 83 (1998) 1247-1252
10. Brandon D.D., Isabelle L.M., Samuels M.H., et al. Cortisol production rate measurement by stable isotope dilution using gas chromatography-negative ion chemical ionization mass spectrometry. Steroids 64 (1999) 372-378
11. Buttgereit F., and Scheffold A. Rapid glucocorticoid effects on immune cells. Steroids 67 (2002) 529-534
12. Barbetta L., Dall'Asta C., Re T., et al. Comparison of different regimens of glucocorticoid replacement therapy in patients with hypoadrenalism. Journal of Endocrinological Investigation 28 (2005) 632-637
13. Alonso N., Granada M.L., Lucas A., et al. Evaluation of two replacement regimens in primary adrenal insufficiency patients. effect on clinical symptoms, health-related quality of life and biochemical parameters. Journal of Endocrinological Investigation 27 (2004) 449-454
14. Laureti S., Falorni A., and Santeusanio F. Improvement of treatment of primary adrenal insufficiency by administration of cortisone acetate in three daily doses. Journal of Endocrinological Investigation 26 (2003) 1071-1075
15. Peacey S.R., Guo C.Y., Robinson A.M., et al. Glucocorticoid replacement therapy: are patients over treated and does it matter?. Clinical Endocrinology 46 (1997) 255-261
16. Howlett T.A. An assessment of optimal hydrocortisone replacement therapy. Clinical Endocrinology 46 (1997) 263-268
17. Mah P.M., Jenkins R.C., Rostami-Hodjegan A., et al. Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clinical Endocrinology 61 (2004) 367-375
18. Arlt W., Rosenthal C., Hahner S., et al. Quality of glucocorticoid replacement in adrenal insufficiency: clinical assessment vs. timed serum cortisol measurements. Clinical Endocrinology 64 (2006) 384-389
19. Lovas K., and Husebye E.S. Continuous subcutaneous hydrocortisone infusion in Addison's disease. European Journal of Endocrinology 157 (2007) 109-112
20. Newell-Price J., Whiteman M., Rostami-Hodjegan A., et al. Modified-release hydrocortisone for circadian therapy: a proof-of-principle study in dexamethasone-suppressed normal volunteers. Clinical Endocrinology 68 (2008) 130-135
21. Johannsson G., Filipsson H., Bergthorsdottir R., et al. Long-acting hydrocortisone for glucocorticoid replacement therapy. Hormone Research 68 Suppl. 5 (2007) 182-188
22. Buttgereit F., Doering G., Schaeffler A., et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet 371 (2008) 205-214
23. Oelkers W., Diederich S., and Bahr V. Diagnosis and therapy surveillance in Addison's disease: rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone. The Journal of Clinical Endocrinology and Metabolism 75 (1992) 259-264
24. Labrie F., Belanger A., Cusan L., et al. Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology. The Journal of Clinical Endocrinology and Metabolism 82 (1997) 2403-2409
25. Martel C., Melner M.H., Gagne D., et al. Widespread tissue distribution of steroid sulfatase, 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase (3 beta-HSD), 17 beta-HSD 5 alpha-reductase and aromatase activities in the rhesus monkey. Molecular and Cellular Endocrinology 104 (1994) 103-111
26. Labrie F. Intracrinology. Molecular and Cellular Endocrinology 78 (1991) C113-C118
27. Allolio B., and Arlt W. DHEA treatment: myth or reality?. Trends in Endocrinology and Metabolism: TEM 13 (2002) 288-294
28. Hammer F., Drescher D.G., Schneider S.B., et al. Sex steroid metabolism in human peripheral blood mononuclear cells changes with aging. The Journal of Clinical Endocrinology and Metabolism 90 (2005) 6283-6289
29. Krazeisen A., Breitling R., Imai K., et al. Determination of cDNA, gene structure and chromosomal localization of the novel human 17beta-hydroxysteroid dehydrogenase type 7(1). FEBS Letters 460 (1999) 373-379
30. Hammer F., Subtil S., Lux P., et al. No evidence for hepatic conversion of dehydroepiandrosterone (DHEA) sulfate to DHEA: in vivo and in vitro studies. The Journal of Clinical Endocrinology and Metabolism 90 (2005) 3600-3605
31. Arlt W., Haas J., Callies F., et al. Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. The Journal of Clinical Endocrinology and Metabolism 84 (1999) 2170-2176
32. Arlt W., Callies F., Koehler I., et al. Dehydroepiandrosterone supplementation in healthy men with an age-related decline of dehydroepiandrosterone secretion. The Journal of Clinical Endocrinology and Metabolism 86 (2001) 4686-4692
33. Callies F., Arlt W., Siekmann L., et al. Influence of oral dehydroepiandrosterone (DHEA) on urinary steroid metabolites in males and females. Steroids 65 (2000) 98-102
34. Bergeron R., de Montigny C., and Debonnel G. Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via sigma receptors. The Journal of Neuroscience 16 (1996) 1193-1202
35. Majewska M.D., Demirgoren S., Spivak C.E., et al. The neurosteroid dehydroepiandrosterone sulfate is an allosteric antagonist of the GABAA receptor. Brain Research 526 (1990) 143-146
36. Petri M.A., Mease P.J., Merrill J.T., et al. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis and Rheumatism 50 (2004) 2858-2868
37. Coles A.J., Thompson S., Cox A.L., et al. Dehydroepiandrosterone replacement in patients with Addison's disease has a bimodal effect on regulatory (CD4+ CD25hi and CD4+ FoxP3+) T cells. European Journal of Immunology 35 (2005) 3694-3703
38. Liu D., and Dillon J.S. Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha(i2,3). The Journal of Biological Chemistry 277 (2002) 21379-21388
39. Liu D., Iruthayanathan M., Homan L.L., et al. Dehydroepiandrosterone stimulates endothelial proliferation and angiogenesis through extracellular signal-regulated kinase 1/2-mediated mechanisms. Endocrinology 149 (2008) 889-898
40. Arlt W., Callies F., van Vlijmen J.C., et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. The New England Journal of Medicine 341 (1999) 1013-1020
41. Hunt P.J., Gurnell E.M., Huppert F.A., et al. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial. The Journal of Clinical Endocrinology and Metabolism 85 (2000) 4650-4656
42. Johannsson G., Burman P., Wiren L., et al. Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism 87 (2002) 2046-2052
43. Brooke A.M., Kalingag L.A., Miraki-Moud F., et al. Dehydroepiandrosterone improves psychological well-being in male and female hypopituitary patients on maintenance growth hormone replacement. The Journal of Clinical Endocrinology and Metabolism 91 (2006) 3773-3779
44. Gurnell E.M., Hunt P.J., Curran S.E., et al. Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial. The Journal of Clinical Endocrinology and Metabolism 93 (2008) 400-409
45. van Thiel S.W., Romijn J.A., Pereira A.M., et al. Effects of dehydroepiandrostenedione, superimposed on growth hormone substitution, on quality of life and insulin-like growth factor I in patients with secondary adrenal insufficiency: a randomized, placebo-controlled, cross-over trial. The Journal of Clinical Endocrinology and Metabolism 90 (2005) 3295-3303
46. Libe R., Barbetta L., Dall'Asta C., et al. Effects of dehydroepiandrosterone (DHEA) supplementation on hormonal, metabolic and behavioral status in patients with hypoadrenalism. Journal of Endocrinological Investigation 27 (2004) 736-741
47. Lovas K., Gebre-Medhin G., Trovik T.S., et al. Replacement of dehydroepiandrosterone in adrenal failure: no benefit for subjective health status and sexuality in a 9-month, randomized, parallel group clinical trial. The Journal of Clinical Endocrinology and Metabolism 88 (2003) 1112-1118
48. Callies F., Fassnacht M., van Vlijmen J.C., et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency: effects on body composition, serum leptin, bone turnover, and exercise capacity. The Journal of Clinical Endocrinology and Metabolism 86 (2001) 1968-1972
49. Dhatariya K., Bigelow M.L., and Nair K.S. Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women. Diabetes 54 (2005) 765-769
50. Kim S.S., and Brody K.H. Dehydroepiandrosterone replacement in addison's disease. European Journal of Obstetrics, Gynecology, and Reproductive Biology 97 (2001) 96-97
51. Allolio B., Hoffmann J., Linton E.A., et al. Diurnal salivary cortisol patterns during pregnancy and after delivery: relationship to plasma corticotrophin-releasing-hormone. Clinical Endocrinology 33 (1990) 279-289
52. Suri D., Moran J., Hibbard J.U., et al. Assessment of adrenal reserve in pregnancy: defining the normal response to the adrenocorticotropin stimulation test. The Journal of Clinical Endocrinology and Metabolism 91 (2006) 3866-3872
53. Lindsay J.R., and Nieman L.K. The hypothalamic-pituitary-adrenal axis in pregnancy: challenges in disease detection and treatment. Endocrine Reviews 26 (2005) 775-799
54. Diederich S., Bahr V., and Oelkers W. Therapy of adrenal cortex insufficiency. Deutsche medizinische Wochenschrift 119 (1994) 595-597
55. Annane D., Sebille V., Charpentier C., et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA : The Journal of the American Medical Association 288 (2002) 862-871
56. Briegel J., Forst H., Haller M., et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Critical Care Medicine 27 (1999) 723-732
57. Sprung C.L., Annane D., Keh D., et al. Hydrocortisone therapy for patients with septic shock. The New England Journal of Medicine 358 (2008) 111-124
58. Dellinger R.P., Levy M.M., Carlet J.M., et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Critical Care Medicine 36 (2008) 296-327
59. Schlaghecke R., Kornely E., Santen R.T., et al. The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. The New England Journal of Medicine 326 (1992) 226-230
60. Nicholson G., Burrin J.M., and Hall G.M. Peri-operative steroid supplementation. Anaesthesia 53 (1998) 1091-1104
61. Henzen C., Suter A., Lerch E., et al. Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet 355 (2000) 542-545
62. Salem M., Tainsh Jr. R.E., Bromberg J., et al. Perioperative glucocorticoid coverage. A reassessment 42 years after emergence of a problem. Annals of Surgery 219 (1994) 416-425
63. Darzy K.H., and Shalet S.M. Circadian and stimulated thyrotropin secretion in cranially irradiated adult cancer survivors. The Journal of Clinical Endocrinology and Metabolism 90 (2005) 6490-6497
64. Allolio B., Kaulen D., Deuss U., et al. Comparison between hydrocortisone and cortisone acetate as replacement therapyin adrenocortical insufficiency. Aktuelle Endokrinologie und Stoffwechsel 6 (1985) 35-39